Little Proteon Therapeutics took a torpedo right at the water line this morning, reporting that its Phase III study of vonapanitase for chronic kidney disease had failed badly.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,